Clinical trials: Tobacco Smoking Behavior
Smoking
CSD170401: Study to Assess Elements of Abuse Liability for Three Electronic Tobacco Vapor Products During an 11-Day In-Clinic Confinement
This study will examine elements of abuse liability (AL) related to potential product adoption of three electronic tobacco vapor products by current smokers relative to high and low AL comparator products (usual brand cigarette…
- Trial name
- NCT03126357
- Testing
- Product A, Product B, Product C
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking Cessation, Tobacco Use Cessation
Efficacy and Safety of Dianicline Treatment as an Aid to Smoking Cessation in Cigarette Smokers (AMERIDIAN)
The primary study objective is to demonstrate the efficacy of dianicline as an aid to smoking cessation in cigarette smokers. The main secondary objectives are to assess the: craving for cigarettes, nicotine withdrawal symptoms…
- Trial name
- NCT00387946
- Testing
- SSR591813L (dianicline)
- Where
- 2 sites in United States, Canada
- Volunteers
- 630 people
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease - COPD
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
To assess the bronchodilation of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID) administered via Pressair® compared to placebo and to open-label nebulized formoterol fumarate (20 μg and 40 μg).
- Trial name
- NCT02796651
- Testing
- Formoterol fumarate (6 μg), Formoterol furmarate (20 μg), Formoterol fumarate (12 μg)
- Where
- 20 sites in United States
- Volunteers
- 132 people
- Sponsor
- AstraZeneca
Smoking, Smoking Behaviors
Abuse Liability of Two Modern Oral Nicotine Pouched Products
This is a single-site, open-label, randomized, 4-way cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics [PD]) and plasma nicotine…
- Conditions
- Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
- Trial name
- NCT07595055
- Testing
- Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette, Modern Oral Pouch Wintergreen-A 9 mg Nicotine, Modern Oral Pouch Wintergreen-B 9 mg Nicotine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Tobacco Use, Tobacco Smoking
A Study to Assess the Pharmacokinetics of Oral Nicotine Pouches and Lozenges in Healthy Adults
This is a randomised, open-label, confined, cross-over study to evaluate the nicotine pharmacokinetics (PK) of modern oral nicotine pouches and nicotine lozenges carried out in 36 healthy adult subjects who smoke cigarettes and…
- Conditions
- Tobacco Use, Tobacco Smoking, Cigarette Smoking
- Trial name
- NCT04755348
- Testing
- Product A, Product B, Product C
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- British American Tobacco (Investments) Limited
Smoking
CSD170302: Study to Assess Nicotine Uptake in Smokers From Electronic Cigarettes
To determine the rate and amount of nicotine uptake with 10-minute ad libitum use of four different marketed electronic cigarettes.
- Trial name
- NCT03233997
- Testing
- FT21018, FT21033, FT21034
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Tobacco Use, Smoking
BRP1602: Evaluation of Technical and Logistical Feasibility to Measure Lung Permeability
This will be a single-center, single-blind, four-cohort, 22-day ambulatory study during which up to 24 healthy adult subjects [6 smokers (SMK), 6 moist snuff consumers (MSC), 6 vapers (VAP), and 6 non-tobacco consumers (NTC)]…
- Conditions
- Tobacco Use, Smoking, Smoking, Tobacco
- Trial name
- NCT06105424
- Testing
- Lung Permeability Assessment
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking, Tobacco Use Disorder
A Pilot Study to Evaluate Safety and Efficacy of CigRx™ in Smokers
A randomized, double-blind, active-controlled, crossover, pilot study to evaluate the safety and efficacy of CigRx™ Lozenge, a dietary supplement, in daily smokers in temporarily reducing the desire to smoke
- Trial name
- NCT01262170
- Testing
- CigRx Lozenge, Tobacco Lozenge
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Rock Creek Pharmaceuticals, Inc.
Smoking Cessation
Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders
This study is being conducted to assess varenicline and bupropion as aids to smoking cessation treatment in subjects with and without an established diagnosis of major psychiatric disorder and to characterize the neuropsychiatric…
- Trial name
- EAGLES (NCT01456936)
- Testing
- varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
- Where
- 156 sites in United States, Argentina and 14 more
- Volunteers
- 8,144 people, healthy volunteers welcome
- Sponsor
- Pfizer
Smoking Abstinence
Effects of AFQ056 and Nicotine in Reducing Cigarette Smoking
The purpose of this study is to assess the safety and efficacy of AFQ056 and nicotine compared to placebo on craving and withdrawal symptoms during voluntary smoking stoppage in healthy smokers.
- Trial name
- NCT00414752
- Testing
- AFQ065
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novartis
Smoking
Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)
The primary objective of this clinical study is to evaluate the pharmacokinetic (PK) profile (rate and amount of nicotine absorbed) following a single use of the THS 2.2 compared to the PK profiles from a single use of a…
- Trial name
- NCT01967732
- Testing
- THS 2.2, CC, NNS
- Where
- United Kingdom
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Smoking
Nicotine Pharmacokinetic Profile of the CHTP 1.1 M
The primary objective of this clinical study is to evaluate the pharmacokinetic (PK) profile of nicotine (rate and amount of nicotine absorbed) after single use of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M), a…
- Trial name
- NCT02466412
- Testing
- CHTP 1.1 M, mCC
- Where
- Japan
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Smoking Cessation
A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation
The purpose of this study is to evaluate NicVAX as an aid to smoking cessation for long term abstinence.
- Trial name
- NCT01102114
- Testing
- NicVAX Vaccine
- Where
- 25 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Nabi Biopharmaceuticals
Smoking, Tobacco Use
CSD201202: A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery System P12
This is an open-label, randomized, 8-way crossover study designed to evaluate plasma nicotine pharmacokinetic (PK) parameters following an ad libitum use of Electronic Nicotine Delivery System (ENDS) investigational products…
- Trial name
- NCT05239884
- Testing
- ENDS Product A with 1.5% nicotine, ENDS Product B with 1.5% nicotine, ENDS Product C with 1.5% nicotine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking, Smoking Behaviors
CSD200907: A Study to Assess Elements of Abuse Liability for a Heated Tobacco Product With Four Non-Combusted Cigarette Variants
This is a single-center, open-label, randomized, 2-arm, within-arm cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics [PD]), and plasma…
- Conditions
- Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
- Trial name
- NCT05114863
- Testing
- Product A1, Product B, Product C
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking, Tobacco Use Disorder
QuitAdvisorMD: A Point-of-care Tool for Brief Smoking Cessation Interventions
QuitAdvisorMD: A point-of-care tool for brief smoking cessation interventions Under a Phase II SBIR grant supported by NIH/NIDA, we are developing QUITAdvisorMD: a point-of-care, patient-centered resource for counseling patients…
- Trial name
- NCT01065493
- Testing
- QuitAdvisorMD Software Algorithm, Standard Smoking Cessation Counseling
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Silverchair Science & Communications, LLC
Smoking Cessation
Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)
This study is a Phase 3, multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group trial to evaluate the efficacy and safety of AXS-05 compared to placebo and bupropion for smoking cessation in adults.
- Trial name
- SUMMIT (NCT07766655)
- Testing
- AXS-05 (dextromethorphan-bupropion), Bupropion
- Where
- 26 sites in United States
- Volunteers
- 705 people
- Sponsor
- Axsome Therapeutics, Inc.
Smoking, Cigarette
A Comparison of Exhaled Carbon Monoxide Measurements Using the iCOquit Smokerlyzer and Vitalograph Breath CO Monitor vs Carboxyhemoglobin From Venous Samples While Validating a Mobile Research Application
The main objective of this study is to determine the accuracy and precision of the iCOquit Smokerlyzer as compared with the gold standard of COHb levels measured in venous plasma samples, as well as assessing its agreement with…
- Trial name
- COCO (NCT04826549)
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Rose Research Center, LLC
Smoking
Evaluation of Environmental Emissions From Electronic Cigarettes and Tobacco-Burning Cigarettes
This study will assess environmental emissions of selected compounds in a test chamber after cigarette smoking or e-cigarette vaping.
- Trial name
- NCT02185898
- Testing
- Leading U.S. non-menthol cigarette, Leading U.S. menthol cigarette, Electronic cigarette #1
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- R.J. Reynolds Vapor Company
Smoking
Reduced Exposure Study Using the CHTP 1.2 With 5 Days in a Confinement Setting Followed by 85 Days in an Ambulatory Setting.
The overall goal of the study is to demonstrate reduction in the levels of biomarkers of exposure (BoExp) to selected harmful and potentially harmful constituents (HPHCs) identified in cigarettes and to obtain safety information…
- Trial name
- NCT02641587
- Testing
- CHTP 1.2, CC
- Where
- Poland
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.